Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma.

Ann Lab Med · 2022 · PMC9057816 · PMID 35470273

Europe PMC DOI

hedged sentence

0.0870

closest p · 1.7× alpha

0.0870

boldest claim

The sentences

showed a trendP =0.087so close (0.05 < p ≤ 0.1)

We further evaluated the impact of MRD in 45 patients who underwent MRD assessment within six months after autologous stem cell transplantation (ASCT), demonstrating that MRD-positive patients showed a trend toward an inferior PFS ( P =0.087) ( Fig. 2E ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.